Document:

AMENDMENT NO. 1 TO RESEARCH
                                    AGREEMENT

This Amendment No. 1 to Research Agreement ("Amendment") is made and entered
into as of November 15, 2002 by and between BioCell Innovations ("Sponsor") and
The University of Texas M.D. Anderson Cancer Center ("Institution"), a component
of the University of Texas System ("System").

RECITALS

A.     Sponsor and Institution entered into a Sponsored Laboratory Research
Agreement dated May 15, 2002 (the "Agreement").

B.     Sponsor and Institution wish to amend the terms of the Agreement as set
forth below.

NOW, THEREFORE, it is hereby agreed as follows:

1.     Section 2 of the Agreement shall be revised to read in its entirety as
follows:

2.     In consideration for performance of the Study by Institution, Sponsor
shall pay Institution Forty Six Thousand Eight Hundred and Seventy Five and
No/100 Dollars ($46,875.00) for Study expenses and other related costs. This
amount, shown by approximate category of expense in Exhibit B attached hereto,
is payable in installments as designated in each by Sponsor to Institution in
the payment schedule provided.

2.     Section 3.1 of the Agreement shall be revised to read in its entirety as
follows:

3.1     This Agreement shall continue in force until the earlier of completion
of the Study as mutually agreed upon by the parties or six (6) months from the
date set forth above; provided, however, that either party may terminate the
Agreement by giving thirty (30) days advance notice to the other.

2.     Except as expressly provided in this Amendment, all other terms,
conditions and provisions of the Agreement shall continue in full force and
effect as provided therein.

<PAGE>

IN WITNESS WHEREOF, Sponsor and Institution have entered into this Amendment
effective as of the date first set forth above.

BIOCELL INNOVATIONS            THE UNIVERSITY OF TEXAS
                               M.D. ANDERSON CANCER CENTER

By /s/                         By /s/
Richard Cole                   Leonard A. Zwelling, M.D., M.B.A.
President and CEO              Vice President for Research Administration

Date: November 15, 2002        Date: November 15, 2002

I have read this Amendment and understand my obligations hereunder:

                                   /s/
                                   Zeev Estrov, MD
                                   Principal Investigator

                                   /s/
                                   Moshe Talpaz, MD
                                   Chairman, Department of Bioimmunotherapy

                                   /s/
                                   Waun Ki Hong, MD
                                   Head, Division of Cancer Medicine

<PAGE>

                                    EXHIBIT B

      "EXPANSION AND DIFFERENTIATION OF BONE MARROW AND BLOOD STEM CELLS INTO
               DIFFERENT LINEAGES USING TISSUE CULTURE TECHNIQUES"

                                Payment Schedule:
                                -----------------

    Installment 1- $15,625.00 USD upon 30 days of execution of this Agreement

    Installment 2- $15,625.00 USD upon 60 days of execution of this Agreement

    Installment 3- $15,625.00 USD upon 90 days of execution of this AgreementCONSULTING AGREEMENT

     This Agreement is made on May 31, 2002 between BioCell Innovations, Inc.
(the "Company") with offices and principal place of business at 6302 Tall Canyon
Court, Katy, Texas 77450 and Zeev Estrov, MD (the "Consultant"), residing at
5739 Birdwood Road, Houston, Texas 77096, and is effective on May 31, 2002. This
agreement supercedes any and all prior agreements by and between the parties,
and to the extent any other agreement between the parties is inconsistent with
this agreement, this agreement controls. Whereas, the Company seeks to benefit
from the Consultant's expertise by retaining the Consultant as a Technical
Consultant; and Whereas, the Consultant wishes to perform consulting services
for the Company. Accordingly, the Company and the Consultant agree as follows:

1.SERVICES
a. The consultant shall provide advice and consulting services to the Company
with respect to matters related to patents and technology independently
developed by Company. The Consultant shall not perform any services for the
Company related to the SPONSORED LABORATORY STUDY AGREEMENT executed by and
between the Company and M. D. Anderson Cancer Center (MDACC) or in conflict
therewith.

b. The Company acknowledges that the Consultant is an employee of MDACC and is
subject to the MDACC's policies, including policies concerning consulting,
conflicts of interest, and intellectual property. If there is a conflict between
Consultant's obligations under MDACC's policies and any of Consultant's
obligations to Company pursuant to this Agreement, the Consultant's obligations
under the MDACC policies take priority over any obligations the Consultant may
have to the Company by reason of this agreement.

2.COMPENSATION
As full consideration for the consulting services provided by the Consultant,
the Company shall pay to the Consultant two thousand dollars ($2000.00) per day.
A day shall be defined as eight (8) hours. Payment shall be made within days of
a submitted bill showing time expended for consulting services. Billing shall be
for day increments and paid at the rate of $1000.00 per day. A minimum of day
shall be paid for any of Consultant's time utilized in any calendar day, except
Consultant will provide a maximum of 4 telephone conversations per month of a
duration not to exceed 10 minutes each for no charge. Company shall also pay all
of Consultant's out-of-pocket expenses incurred for performance of this
agreement provided they are approved in advance by Company, which approval shall
not be unreasonably withheld. Consultant's services shall be performed on
Consultant's own time and not during any time period for which Consultant is
being paid by MDACC,

3.COMPETITION
The Consultant represents to the Company that the Consultant does not have any
agreement to provide consulting services to any other party, firm, or company in
the on matters relating to the scope of this consultancy, and will not enter
into any such agreement during the term of this Agreement without written
agreement of Company. The Company acknowledges and agrees, however, that nothing
in this Agreement shall affect the Consultant's obligations to, or research on
behalf of, MDACC or any component of The University of Texas System, including,
without limitation, obligations or research of the Consultant in connection with
a transfer by MDACC of materials or intellectual property developed in whole or
in part by the Consultant, or in connection with research collaborations.

<PAGE>

4.CONFIDENTIALITY
a. Either party may disclose to the other party any information that the
disclosing party would normally freely disclose to the other members of the
scientific community at large, whether by publication, by presentation at
seminars, or in informal scientific discussions.

b. The parties may wish, from time to time, in connection with work contemplated
under this Agreement, to disclose confidential information to each other
("Confidential Information"). Each party will use reasonable efforts to prevent
the disclosure of any of the other party's Confidential Information to third
parties for a period of three (3) years from receipt thereof. The recipient may
acquire information that pertains to the discloser's processes, equipment,
programs, developments, or plans that is both (i) disclosed or made known by the
disclosure to the recipient and (ii) identified in writing as "proprietary" by
the disclosure. The recipient agrees not to disclose any Confidential
Information to third parties or to use any Confidential Information for any
purpose other than performance of the services contemplated by this Agreement,
without prior written consent of the Company.

c. Confidential Information subject to paragraph 4(b) does not include
information that (i) is or later becomes available to the public through no
breach of this Agreement by the recipient; (ii) is obtained by the recipient
from a third party who had the legal right to disclose the information to the
recipient; (iii) is already in the possession of the recipient on the date this
Agreement becomes effective; (iv) is independently developed by recipient; or
(v) is required to be disclosed by law, government regulation, or court order.
In addition, Confidential Information subject to paragraph 4(b) does not include
information generated by the Consultant unless the information (i) is generated
as a direct result of the performance of consulting services under this
Agreement and (ii) is not generated in the course of the Consultant's activities
as a MDACC employee or faculty member.

d. Notwithstanding any of the other terms of this Agreement, and in exception
thereto, the parties to this Agreement acknowledge and agree that Consultant is
an employee of The University of Texas M. D. Anderson Cancer Center and
therefore Consultant executes this Agreement subject to the Rules and
Regulations of The Board of Regents of The University of Texas System and all
terms and conditions therein which apply to Consultant and any information
subject to ownership of The Board of Regents according to these Rules and
Regulations shall not be considered the confidential information of the party
contracting with Consultant

5.RETURN OF MATERIALS
The Consultant agrees to promptly return, following the termination of this
Agreement or upon earlier request by the Company, all drawings, tracings, and
written materials in the Consultant's possession and (i) supplied by the Company
in conjunction with the Consultant's consulting services under this Agreement or
(ii) generated by the Consultant in the performance of consulting services under
this Agreement and not generated in the course of the Consultant's activities as
an MDACC employee or faculty member.

6.INTELLECTUAL PROPERTY
a. Title to all inventions and discoveries made by Consultant resulting from the
work performed hereunder shall reside in MDACC; title to all inventions and
discoveries made by Company resulting from the research performed hereunder
shall reside in Company. Notwithstanding any of the other terms of this
Agreement, and in exception thereto, the parties to this Agreement acknowledge
and agree that Consultant is an employee of The University of Texas M. D.
Anderson Cancer Center and therefore Consultant executes this Agreement subject
to the Rules and Regulations of The Board of Regents of The University of Texas
System and all terms and conditions therein which apply to Consultant and any
ownership of any intellectual property shall be in accordance with the Rules and
Regulations of The Board of Regents of The University of Texas System and all
terms and conditions therein which apply to Consultant.
b. Company shall uphold the agreement it has with MDACC with respect to
intellectual property.

     7.DEFENSE  AND  INDEMNIFICATION
The company agrees, at its sole expense, to defend the Consultant and MDACC
against, and to indemnify and hold the Consultant and MDACC harmless from, any
claims or suits by a third party against the Consultant or MDACC or any
liabilities or judgments based thereon, either arising from the Consultant's
performance of services for the Company under this Agreement.

<PAGE>

8.TERM AND TERMINATION
a. This Agreement shall be for a term of twenty-four (24) months, renewable upon
reasonable terms and conditions as may be agreed upon by the Company and the
Consultant.

b. Termination of the Agreement under paragraph 8(a) above shall not affect (a)
the Company's obligation to pay for services previously performed by the
Consultant or expenses reasonably incurred by the Consultant for which the
Consultant is entitled to reimbursement under paragraph 2, above, (b) the
Company's obligations to recognize the priority of MDACC's intellectual property
rights under paragraph 6(b), above, (c) the Company's obligation to defend and
indemnify the Consultant and the MDACC under paragraph 7 above, or (d) the
Consultant's continuing obligations to the Company under paragraphs 4(b) and
6(a), above.

     9.MISCELLANEOUS
a. This Agreement shall inure to the benefit of and be binding upon the
respective heirs, executors, successors, representatives, and assigns of the
parties, as the case may be.

b. The relationship created by this Agreement shall be that of independent
contractor, and the Consultant shall have no authority to bind or act as agent
for the Company or its employees for any purpose.

c. The Company will not use the Consultant's or MDACC's name in any commercial
advertisement or similar material used to promote or sell products, unless the
Company obtains in advance the written consent of both the Consultant and MDACC.

d. Notice or payments given by one party to the other hereunder shall be in
writing and deemed to have been properly given or paid if deposited with the
United States Postal Service with a copy thereof sent to the parties by email,
to Company at rcole@pdq.net and drudd@biocellinnovations.com and to Consultant
at zestrov@pdq.net or such address as may be provided to the parties from time
to time.

e. This Agreement replaces all previous agreements and the discussions relating
to the subject matters hereof and constitutes the entire agreement between the
Company and the Consultant with respect to the subject matters of this
Agreement. This Agreement may not be modified in any respect by any verbal
statement, representation, or agreement made by any employee, officer, or
representative of the Company, or by any written documents unless it is signed
by an officer of the Company and by the Consultant.

f. If any term or provision of this Agreement is deemed invalid, contrary to, or
prohibited under applicable laws or regulation of any jurisdiction, this
Agreement (save only this sentence) shall be invalid.

IN WITNESS WHEREOF, the parties have executed this Agreement effective the date
first stated above.

By: /s/ Richard Cole
     President

By: /s/ Zeev Estrov
Consultant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]